Industry Trends

With revenues down and margins squeezed by a realigning payer pool, the power to price above the market is the ticket to the top-no discounts allowed.

Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."

Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what?

Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.

Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.

As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.

The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry-for good or bad-in 2012.

Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.

Is the 'lost decade' of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so...

Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.

Meet the rest of 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history?

As the old Broadway song goes, June is busting out all over-and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.

Clayton Christensen, author of "The Innovator's Dilemma", offers to collaborate with pharma CEOs on solutions to the strategic impasse around flagging drug productivity.

The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.

More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.

Sponsor sourcing requirements are diverging from the operating needs and long-term strategies of the major CROs.

Preliminary results from BioPlan Associates' 9th Annual Report and Survey of Biomanufacturing suggest there's a good reason to be optimistic about 2012.

Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.

Top 10 Companies by Market Share

Pharm Exec celebrates its 30th birthday with a gathering of 30 of the industry's key influencers of the last three decades.

30 Years of Pharma: Perspective in Numbers

Top 10 Products Worldwide

Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies.

What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era.

William Looney, Editor-in-Chief, last month took home the award for "Best Commentary"

Negative views regarding pharma are on the rise, but vaccines help keep the focus on the positives of innovation

Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story

"Tops in Fraud" is a ruinous moniker for pharma-a business so dependent on basic issues of trust, integrity, quality and safety

It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!